Results from trials were negative in two phase 2 studies for Gilead (GILD) experimental drug GS-4997 (selonsertib) intended to treat pulmonary arterial hypertension (PAH) and diabetic kidney disease (DKD). But the same drug selonsertib showed it might hit the jackpot when results demonstrated it succeeded in treating nonalcoholic steatohepatitis (NASH), which is also known as non-alcoholic fatty liver disease, where, according to Gilead, it showed anti-fibrotic activity in an open-label Phase 2 study.
With regard to the PAH and DKD, Gilead stated that due to insufficient evidence of efficacy, it . . .
This content is for paid subscribers.
Today’s Highlights October 21, 2016